the Efficacy and Safety of CLAE in R/R T-ALL/LBL

NCT04679506 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2020-12-22

No results posted yet for this study

Summary

To evaluate the efficacy and safety of CLAE regimen (cladribine + cytarabine + etoposide) in the treatment of relapsed/refractory T-ALL/LBL.

Conditions

  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Interventions

DRUG

Cladribine

CLAE regimen (cladribine + cytarabine + etoposide) for reinduction of R/R T-ALL/LBL

Sponsors & Collaborators

  • Peking University Third Hospital

    lead OTHER

Principal Investigators

  • Hongmei Jing, MD, phD · Peking University Third Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-31
Primary Completion
2021-12-31
Completion
2023-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04679506 on ClinicalTrials.gov